Clinical trial
Treatment of Hepatitis in Patients Who Are Triple-Infected With HIV, Hepatitis B…
NCT00051077 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Withdrawn
Key facts
| NCT number | NCT00051077 |
|---|---|
| Title | Treatment of Hepatitis in Patients Who Are Triple-Infected With HIV, Hepatitis B Virus (HBV), and Hepatitis C Virus (HCV) |
| Official title | A Phase II Study of Adefovir Dipivoxil, Pegylated Interferon Alfa-2A, and Ribavirin Treatment in HBV and HCV Infected Subjects With HIV Disease |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Status | Withdrawn |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | HIV Infections, Hepatitis B, Hepatitis C |
| Intervention type | Drug, Procedure |
| Interventions | Adefovir dipivoxil, Peginterferon-alfa-2A, Ribavirin, Liver Biopsy |
| Enrollment | 0 |
| First posted | Jan 6, 2003 |
| Last update posted | Nov 1, 2021 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: